The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | R | Respiratory system | |
| 2 | R01 | Nasal preparations | |
| 3 | R01A | Decongestants and other nasal preparations for topical use | |
| 4 | R01AA | Sympathomimetics, plain | |
| 5 | R01AA07 | Xylometazoline |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| NASAL - Nasal | 0.8 mg |
| Active Ingredient | Description | |
|---|---|---|
| Xylometazoline |
Xylometazoline acts directly on α-adrenoreceptors but does not act on β-receptors. When used topically as a nasal decongestant, xylometazoline acts rapidly and provides long-lasting relief. Onset of action is within minutes, the decongestant effect being prolonged and lasting for up to 10 hours. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| OTRIVIN ADULT Menthol Nasal spray, solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| OTRIVINE ADULT Nasal spray, solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
